
News|Articles|March 31, 2015
The Impact of CTCs on Survival in Cervical Cancer
Krishnansu S. Tewari, MD, FACOG, FACS, discusses a trial looking at the impact of CTCs on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
Advertisement
Krishnansu S. Tewari, MD, FACOG, FACS, Professor and Director of Research, Principal Investigator, NRG Oncology and GOG Legacy, University of California Irvine, discusses a trial looking at the impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer.
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















